Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy

[1]  Ross Berbeco,et al.  Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer , 2014, PloS one.

[2]  E. Yorke,et al.  Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[3]  M. Hatt,et al.  Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer , 2014, The Journal of Nuclear Medicine.

[4]  Aaron D Ward,et al.  Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.

[5]  Irène Buvat,et al.  Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion Glycolysis , 2014, The Journal of Nuclear Medicine.

[6]  D. Heron,et al.  Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy , 2014, Radiation oncology.

[7]  F. Brooks,et al.  The Effect of Small Tumor Volumes on Studies of Intratumoral Heterogeneity of Tracer Uptake , 2014, The Journal of Nuclear Medicine.

[8]  E. Kunieda,et al.  Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after Stereotactic Body Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Chun-Ta Liao,et al.  Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma , 2013, The Journal of Nuclear Medicine.

[10]  F. Sterzing,et al.  Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  S. T. Astner,et al.  Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy , 2013, Strahlentherapie und Onkologie.

[12]  Makoto Kajihara,et al.  Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings , 2013, Annals of Nuclear Medicine.

[13]  V. Goh,et al.  Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? , 2013, The Journal of Nuclear Medicine.

[14]  Jan-Jakob Sonke,et al.  Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. , 2012, International journal of radiation oncology, biology, physics.

[15]  S. Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[16]  John Cho,et al.  Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  M. Hatt,et al.  Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.

[18]  John Cho,et al.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. , 2012, International journal of radiation oncology, biology, physics.

[19]  Toshio Ohashi,et al.  The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Michael Molls,et al.  Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Ronald Boellaard,et al.  Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  M. Hatt,et al.  Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.

[23]  Tomio Inoue,et al.  Deep-inspiration breath-hold PET/CT versus free breathing PET/CT and respiratory gating PET for reference: evaluation in 95 patients with lung cancer , 2011, Annals of nuclear medicine.

[24]  H. Groen,et al.  18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  C. Reddy,et al.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[26]  E. Oermann,et al.  CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment , 2010, Journal of hematology & oncology.

[27]  F. O’Sullivan,et al.  Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome , 2008, Journal of Nuclear Medicine.

[28]  I. Buvat,et al.  Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.

[29]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. , 2005, Lung cancer.

[30]  V. Goh,et al.  Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. , 2013, Radiology.

[31]  Vicky Goh,et al.  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  M Schwaiger,et al.  PET/CT Biograph Sensation 16. Performance improvement using faster electronics. , 2006, Nuklearmedizin. Nuclear medicine.